| 43.7 1.73 (4.12%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 53.55 |
1-year : | 62.54 |
| Resists | First : | 45.84 |
Second : | 53.55 |
| Pivot price | 42.56 |
|||
| Supports | First : | 42.72 |
Second : | 40.79 |
| MAs | MA(5) : | 42.21 |
MA(20) : | 42.84 |
| MA(100) : | 41.06 |
MA(250) : | 33.07 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 38.7 |
D(3) : | 26 |
| RSI | RSI(14): 54.4 |
|||
| 52-week | High : | 48.61 | Low : | 15.43 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RVMD ] has closed below upper band by 16.3%. Bollinger Bands are 38.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 44.04 - 44.21 | 44.21 - 44.38 |
| Low: | 41.81 - 42.01 | 42.01 - 42.21 |
| Close: | 43.37 - 43.68 | 43.68 - 44 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Fri, 13 Sep 2024
Victory Capital Management Inc. Trims Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Thu, 12 Sep 2024
Nicholas Investment Partners LP Takes Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Wed, 11 Sep 2024
10 Largest Biotech Hedge Funds and Their Top Stock Picks - Insider Monkey
Mon, 09 Sep 2024
Revolution Medicines: It's Full Steam Ahead, But I Wouldn't Buy At These Levels - Seeking Alpha
Wed, 31 Jul 2024
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024 - StockTitan
Mon, 15 Jul 2024
Revolution Medicines Balances 2024 Loss Projection with Promising Cancer Drug Trials - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 167 (M) |
| Held by Insiders | 1.5333e+008 (%) |
| Held by Institutions | 2.3 (%) |
| Shares Short | 15,760 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.6947e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -77 % |
| Return on Assets (ttm) | 524.6 % |
| Return on Equity (ttm) | -25 % |
| Qtrly Rev. Growth | 742000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -28.29 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -510 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.55 |
| Price to Cash Flow | 6.44 |
| Dividend | 0 |
| Forward Dividend | 1.684e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|